Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by year, source, volume, issue, page.
Page 3: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
601 | 0 | 0 | 601 1997 FORTUNE 136(6):36-& McLean B Thalidomide .2. | 0 | 0 |
602 | 11 | 39 | 602 1997 GASTROENTEROLOGY 112(6):1823-1829 Sharpstone D; Rowbottom A; Francis N; Tovey G; Ellis D; Barrett M; Gazzard B Thalidomide: A novel therapy for microsporidiosis | 12 | 42 |
603 | 8 | 22 | 603 1997 IMMUNOPHARMACOLOGY 35(3):203-212 Shannon EJ; Morales MJ; Sandoval F Immunomodulatory assays to study structure-activity relationships of thalidomide | 10 | 13 |
604 | 8 | 21 | 604 1997 IMMUNOPHARMACOLOGY 36(1):9-15 Shannon EJ; Sandoval F; Krahenbuhl JL Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha | 18 | 19 |
605 | 5 | 35 | 605 1997 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 19(3):313-326 Aseffa A; Dietrich MA; Shannon EJ Effect of thalidomide on apoptosis of lymphocytes and neutrophils | 4 | 5 |
606 | 8 | 21 | 606 1997 INFLAMMATION RESEARCH 46(10):392-397 Schneider J; Bruckmann W; Zwingenberger K Extravasation of leukocytes assessed by intravital microscopy: Effect of thalidomide | 5 | 13 |
607 | 48 | 74 | 607 1997 INTERNATIONAL JOURNAL OF DERMATOLOGY 36(12):881-887 Calderon P; Anzilotti M; Phelps R Thalidomide in dermatology. New indications for an old drug | 22 | 27 |
608 | 15 | 27 | 608 1997 INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY 19(5):289-296 Pham-Huy C; Galons H; Voisin J; Zhu JR; Righenzi S; Warnet JM; Claude JR; Duc HT In vitro and in vivo immunosuppressive potential of thalidomide and its derivative, N-hydroxythalidomide, alone and in combination with cyclosporin A | 1 | 1 |
609 | 9 | 21 | 609 1997 INTERNATIONAL JOURNAL OF ONCOLOGY 10(5):965-969 Nguyen M; Tran C; Barsky S; Sun JR; McBride W; Pegram M; Pietras R; Love S; Glaspy J Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies | 20 | 26 |
610 | 0 | 0 | 610 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):1240-1240 Lesk MR; Ponomarenko S; Filion B; Burnier M Effect of oral thalidomide on prolongation of rabbit sclerostomy function. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
611 | 0 | 2 | 611 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):1680-1680 Joussen AM; Kruse FE; Becker M; Rohrschneider K; Volcker HE Thalidomide inhibits angiogenesis induced by vascular endothelial growth factor | 0 | 0 |
612 | 0 | 0 | 612 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):4467-4467 DAmato RJ; Verheul HMW; Panigrahy D; Yuan J Combination antiangiogenic therapy with thalidomide and nonsteroidal anti-inflammatory drugs (NSAIDs) | 0 | 0 |
613 | 0 | 0 | 613 1997 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 38(4):5409-5409 Baatz H; Tonnessen B; Pleyer U; Hartmann C Thalidomide inhibits leukocyte-endothelium-interaction in endotoxin-induced uveitis | 0 | 0 |
614 | 0 | 0 | 614 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(5):379-379 Nightingale SL Workshop on thalidomide | 0 | 0 |
615 | 0 | 0 | 615 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(14):1135-1137 Marwick C Thalidomide back - Under strict control | 10 | 13 |
616 | 0 | 0 | 616 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):20-20 Welles L; Little R; Wyvill K; Pluda J; Figg W; Lietzau J; Merced T; Humphrey R; Yarchoan R Preliminary results of a phase II study of oral thalidomide in patients with HIV infection and Kaposi's sarcoma (KS) | 2 | 3 |
617 | 0 | 0 | 617 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 14(4):76-76 Bower M; Howard M; Gracie F; Phillips R; Fife K A phase II study of thalidomide for Kaposi's sarcoma: Activity and correlation with KSHV DNA load | 1 | 2 |
618 | 3 | 4 | 618 1997 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 15(5):392-392 Sharp M; Getty J; Klausner JD Thalidomide use is associated with weight gain in HIV-1-positive clients | 2 | 2 |
619 | 0 | 0 | 619 1997 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 99(1):679-679 James DE; Jaffarian A; Biggs DF The effects of thalidomide on TNF alpha production from guinea pig alveolar macrophages in vitro and on airways' hyperresponsiveness in vivo. | 0 | 0 |
620 | 18 | 23 | 620 1997 JOURNAL OF AOAC INTERNATIONAL 80(4):767-773 Reepmeyer JC; Cox DC Liquid chromatographic determination of thalidomide in tablets, capsules, and raw materials | 0 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
621 | 10 | 30 | 621 1997 JOURNAL OF IMMUNOLOGY 159(10):5157-5161 Moller DR; Wysocka M; Greenlee BM; Ma XJ; Wahl L; Flockhart DA; Trinchieri G; Karp CL Inhibition of IL-12 production by thalidomide | 77 | 114 |
622 | 0 | 0 | 622 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):179-179 Nasca MR; OToole EA; Palicharla P; West DP; Woodley DT Thalidomide increases both human keratinocyte proliferation and migration | 0 | 0 |
623 | 0 | 0 | 623 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):721-721 Hughes MH; Brander TR; Aronson IK; Eilers D; Fiedler BC Thalidomide therapy for discoid and systemic lupus erythematosus. | 0 | 0 |
624 | 0 | 0 | 624 1997 JOURNAL OF INVESTIGATIVE DERMATOLOGY 108(4):797-797 Wong J; Brocato D; Kumar R The effect of thalidomide on murine hemangioendothelioma | 0 | 0 |
625 | 0 | 10 | 625 1997 JOURNAL OF PARENTERAL AND ENTERAL NUTRITION 21(4):233-234 Vromen A; Spira RM; Bercovier H; Berry E; Freund HR Pentoxifylline and thalidomide fail to reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat | 0 | 2 |
626 | 1 | 3 | 626 1997 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 25(2):250-251 Odeka EB; Miller V Thalidomide in oral Crohn's disease refractory to conventional medical treatment | 17 | 0 |
627 | 0 | 0 | 627 1997 JOURNAL OF THE NATIONAL CANCER INSTITUTE 89(20):1480-1481 Saphir A Jekyll and Hyde: A new license for thalidomide? | 5 | 7 |
628 | 0 | 0 | 628 1997 JOURNAL OF WOMENS HEALTH 6(6):614-615 White K Thalidomide may be approved after decades-long US ban | 0 | 0 |
629 | 0 | 0 | 629 1997 LANCET 349(9045):111-111 Barnett AA Company applies to market thalidomide in USA | 0 | 0 |
630 | 0 | 1 | 630 1997 LANCET 350(9081):873-873 Ault A Thalidomide comes close to US approval | 1 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
631 | 2 | 5 | 631 1997 LANCET 350(9089):1445-1446 Wettstein AR; Meagher AP Thalidomide in Crohn's disease | 35 | 53 |
632 | 6 | 16 | 632 1997 LEPROSY REVIEW 68(1):61-66 Powell RJ; GardnerMedwin JMM Guideline for the clinical use and dispensing of thalidomide (Reprinted from the Postgraduate Medical Journal, vol 70, pg 901-904, 1994) | 1 | 3 |
633 | 5 | 6 | 633 1997 M S-MEDECINE SCIENCES 13(4):595-596 Audit CO; Aimar C Thalidomide-induced teratogenesis. | 0 | 0 |
634 | 21 | 108 | 634 1997 MEDICAL HYPOTHESES 49(2):123-131 McCarty MF Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis | 17 | 31 |
635 | 8 | 59 | 635 1997 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 396(1-2):45-64 Ashby J; Tinwell H; Callander RD; Kimber I; Clay P; Galloway SM; Hill RB; Greenwood SK; Gaulden ME; Ferguson MJ; Vogel E; Nivard M; Parry JM; Williamson J Thalidomide: lack of mutagenic activity across phyla and genetic endpoints | 12 | 14 |
636 | 3 | 9 | 636 1997 NATURE 385(6614):303-304 Wnendt S; Zwingenberger K Thalidomide's chirality | 9 | 16 |
637 | 2 | 5 | 637 1997 NATURE 389(6647):118-118 Ashby J Thalidomide is not a mutagen | 3 | 4 |
638 | 0 | 0 | 638 1997 NATURE BIOTECHNOLOGY 15(11):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 1 |
639 | 0 | 0 | 639 1997 NATURE BIOTECHNOLOGY 15(12):1238-1239 Brower V Thalidomide checks might have saved Redux | 0 | 0 |
640 | 0 | 0 | 640 1997 NATURE MEDICINE 3(1):8-8 Cimons M Thalidomide resurfaces for FDA consideration | 1 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
641 | 0 | 0 | 641 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 355(4):545-545 Stahl W; Nicolai S; Sies H Stimulation of gap junctional communication by thalidomide and thalidomide analogs in human skin fibroblasts | 0 | 0 |
642 | 6 | 29 | 642 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 356(5):529-535 Dunzendorfer S; Schratzberger P; Reinisch N; Kahler CM; Wiedermann CJ Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine-and endotoxin-activated endothelium | 17 | 23 |
643 | 3 | 29 | 643 1997 NEUROSCIENCE LETTERS 234(2-3):123-126 Boireau A; Bordier F; Dubedat P; Peny C; Imperato A Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice | 0 | 9 |
644 | 21 | 44 | 644 1997 NEW ENGLAND JOURNAL OF MEDICINE 336(21):1487-1493 Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection | 119 | 192 |
645 | 3 | 3 | 645 1997 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1086-1087 Birnkrant D Thalidomide for aphthous ulcers in HIV infection | 1 | 2 |
646 | 0 | 1 | 646 1997 NEW ENGLAND JOURNAL OF MEDICINE 337(15):1087-1087 Jacobson JM; Greenspan JS; Spritzler J Thalidomide for aphthous ulcers in HIV infection - Reply | 0 | 0 |
647 | 10 | 20 | 647 1997 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 84(4):362-364 Elad S; Galili D; Garfunkel AA; Or R Thalidomide-induced perioral neuropathy | 2 | 3 |
648 | 5 | 32 | 648 1997 RESPIRATORY MEDICINE 91(1):31-39 Tavares JL; Wangoo A; Dilworth P; Marshall B; Kotecha S; Shaw RJ Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages | 24 | 39 |
649 | 0 | 2 | 649 1997 SCIENTIST 11(3):1-& Brown KS New uses for thalidomide yielding valuable lessons | 1 | 4 |
650 | 1 | 1 | 650 1997 SCIENTIST 11(3):8-8 Brown KS Researchers explore thalidomide's therapeutic potential | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
651 | 0 | 0 | 651 1997 SEARCH 28(8):239-239 [Anon] Inheriting thalidomide deformities | 0 | 0 |
652 | 3 | 13 | 652 1997 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):1-5 Huang PHT; McBride WG Interaction of [glutarimide-2-C-14]-thalidomide with rat embryonic DNA in vivo | 7 | 12 |
653 | 4 | 11 | 653 1997 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):R1-R2 Neubert D Never-ending tales of the mode of the teratogenic action of thalidomide | 3 | 5 |
654 | 6 | 28 | 654 1997 TUBERCLE AND LUNG DISEASE 78(1):47-55 Moreira AL; Tsenova-Berkova L; Wang J; Laochumroonvorapong P; Freeman S; Freedman VH; Kaplan G Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis | 21 | 46 |
655 | 0 | 0 | 655 1998 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 216:U267-U267 Swartz GM; Shah JH; Fogler WE; Papathanassiu A; Madsen JW; Green SJ 2-methyl-2-phthalimidino-glutaric acid, a partially-reduced analog of thalidomide, is a potent inhibitor of B16 melanoma metastases. | 0 | 0 |
656 | 2 | 8 | 656 1998 AIDS 12(3):334-335 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M Effects of thalidomide therapy in symptomatic simian immunodeficiency virus-infected cynomolgus monkeys | 0 | 0 |
657 | 0 | 0 | 657 1998 AIDS PATIENT CARE AND STDS 12(3):231-231 [Anon] Thalidomide studied in asymptomatic patients | 0 | 0 |
658 | 7 | 10 | 658 1998 AIDS PATIENT CARE AND STDS 12(12):903-906 Fu CS; Conteas CN; LaRiviere MJ Successful treatment of idiopathic colitis and proctitis using thalidomide in persons infected with human immunodeficiency virus | 2 | 3 |
659 | 0 | 0 | 659 1998 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 55(17):1746-+ Kepple SR Thalidomide approval brings tight restrictions on access | 1 | 1 |
660 | 11 | 25 | 660 1998 ANNALS OF INTERNAL MEDICINE 128(6):443-+ Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial | 67 | 127 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
661 | 5 | 19 | 661 1998 ANNALS OF INTERNAL MEDICINE 128(6):494-495 Ehrlich GE Behcet disease and the emergence of thalidomide | 4 | 19 |
662 | 3 | 24 | 662 1998 ANTICANCER RESEARCH 18(6A):4409-4413 Browne WL; Wilson WR; Baguley BC; Ching LM Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid | 5 | 13 |
663 | 6 | 26 | 663 1998 ARCHIV DER PHARMAZIE 331(1):7-12 Teubert U; Zwingenberger K; Wnendt S; Eger K 5 '-substituted thalidomide analogs as modulators of TNF-alpha | 10 | 10 |
664 | 4 | 5 | 664 1998 ARCHIVES OF DERMATOLOGY 134(8):1045-1046 Rousseau L; Beylot-Barry M; Doutre MS; Beylot C Cutaneous sarcoidosis successfully treated with low doses of thalidomide | 12 | 25 |
665 | 0 | 0 | 665 1998 ARTHRITIS AND RHEUMATISM 41(9):S60-S60 Scoville CD Open trial using methotrexate and thalidomide in the treatment of rheumatoid arthritis. | 2 | 2 |
666 | 0 | 0 | 666 1998 ARTHRITIS AND RHEUMATISM 41(9):S98-S98 Oliver SJ; Freeman SL; Kaplan G Thalidomide and analog CC1089 in rat adjuvant arthritis. | 0 | 0 |
667 | 0 | 0 | 667 1998 ARTHRITIS AND RHEUMATISM 41(9):S108-S108 Ordi-Ros J; Cortes F; Martinez N; Montse M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease. | 0 | 0 |
668 | 6 | 13 | 668 1998 ARTHRITIS AND RHEUMATISM 41(12):2273-2275 Ordi J; Cortes F; Martinez N; Mauri M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease | 13 | 20 |
669 | 0 | 0 | 669 1998 ASM NEWS 64(10):557-558 Fox JL Thalidomide approved for treating leprosy | 1 | 1 |
670 | 11 | 27 | 670 1998 BIOCHEMICAL PHARMACOLOGY 55(11):1827-1834 Bauer KS; Dixon SC; Figg WD Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent | 82 | 122 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
671 | 5 | 15 | 671 1998 BIOLOGICAL & PHARMACEUTICAL BULLETIN 21(6):638-640 Ishikawa M; Kanno S; Takayanagi M; Takayanagi Y; Sasaki K Thalidomide promotes the release of tumor necrosis factor-alpha (TNF-alpha) and lethality by lipopolysaccharide in mice | 5 | 6 |
672 | 7 | 20 | 672 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(9):1071-1076 Niwayama S; Loh C; Turk BE; Liu JO; Miyachi H; Hashimoto Y Enhanced potency of perfluorinated thalidomide derivatives for inhibition of LPS-induced tumor necrosis factor-alpha production is associated with a change of mechanism of action | 9 | 11 |
673 | 4 | 13 | 673 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(19):2669-2674 Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen YX; Stirling DI Thalidomide analogs and PDE4 inhibition | 21 | 32 |
674 | 0 | 0 | 674 1998 BIOTECHNOLOGY LAW REPORT 17(3):361-362 [Anon] FDA grants orphan drug designation to thalidomide as treatment for primary brain cancers | 0 | 0 |
675 | 0 | 0 | 675 1998 BIOTECHNOLOGY LAW REPORT 17(5):596-597 [Anon] Notorious teratogen wins FDA approval for leprosy - Thalidomide will be most tightly regulated drug ever | 0 | 0 |
676 | 0 | 0 | 676 1998 BLOOD 92(10):235B-235B Costa PT; Leaf RMLV; Morais LO; Ribeiro RA Thalidomide (TLD) and pentoxifylline (PTX) prevent the development of chronic cardiomyopathy provoked by doxorubicin (DXR) in rats without inhibiting its antitumoral effect. | 0 | 2 |
677 | 0 | 0 | 677 1998 BLOOD 92(10):279B-279B Lim SH; Maclean R Thalidomide in IgA multiple myeloma. | 0 | 0 |
678 | 0 | 0 | 678 1998 BLOOD 92(10):318A-318A Singhal S; Mehta J; Eddlemon P; Gray P; Cromer J; Desikan R; Ayers D; Siegel D; Munshi N; Anaissie E; Kantarjian H; Zeldis J; Barlogie B Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). | 0 | 20 |
679 | 0 | 0 | 679 1998 BLOOD 92(10):344B-344B Kulkarni S; Powles R; Mehta J; Horton C; Treleaven J; Meller S; Atra A; Pinkerton CR; Singhal S Thalidomide in GVHD - S anti-GVHD effect separable from the antiangiogenesis? | 0 | 4 |
680 | 0 | 0 | 680 1998 BONE MARROW TRANSPLANTATION 21:S113-S113 Anagnostopoulos A; Fassas A; Giannaki E; Sakellari I; Tzarou V; Smias C; Lalayanni C; Papaioannou G; Gakos E Treatment of resistant chronic GVHD with thalidomide. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
681 | 14 | 23 | 681 1998 BONE MARROW TRANSPLANTATION 21(6):577-581 Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasiulli A; Vassallo E; Miniero R; Uderzo C The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children | 27 | 37 |
682 | 5 | 7 | 682 1998 BONE MARROW TRANSPLANTATION 22(9):933-934 Sastry PSRK; Powles RL Thalidomide for chronic GVHD | 0 | 0 |
683 | 1 | 1 | 683 1998 BONE MARROW TRANSPLANTATION 22(9):934-934 Kami M; Ogawa S; Mitani K; Hirai H Thalidomide for chronic GVHD - Reply | 0 | 0 |
684 | 7 | 24 | 684 1998 BRITISH JOURNAL OF CANCER 78(3):336-343 Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity | 16 | 27 |
685 | 2 | 3 | 685 1998 BRITISH MEDICAL JOURNAL 316(7125):149-149 Smithells D Dominant gene probably caused some of defects ascribed to thalidomide | 1 | 1 |
686 | 11 | 41 | 686 1998 CHEMICAL RESEARCH IN TOXICOLOGY 11(12):1521-1528 Reist M; Carrupt PA; Francotte E; Testa B Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites | 15 | 17 |
687 | 0 | 0 | 687 1998 CHEMISTRY & INDUSTRY (15):591-591 [Anon] Concern over US thalidomide approval | 1 | 0 |
688 | 10 | 23 | 688 1998 CHIRALITY 10(3):223-228 Eriksson T; Bjorkman S; Roth B; Fyge A; Hoglund P Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis | 17 | 28 |
689 | 0 | 0 | 689 1998 CIRCULATION 98(17):247-247 Dibbs ZI; Longo T; Muller GW; Zeldis J; Sivasubramanian N; Mann DL Thalidomide and thalidomide analogs suppress TNF alpha secretion by myocytes | 0 | 0 |
690 | 7 | 10 | 690 1998 CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(3):141-141 Georgala S; Katoulis AC; Hasapi V; Koumantaki-Mathioudaki E Thalidomide treatment for hypertrophic lupus erythematosus | 3 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
691 | 6 | 10 | 691 1998 CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(5):233-235 Herranz P; Pizarro A; de Lucas R; Arribas JR; Garcia-Tobaruela A; Pena JM; Casado M Treatment of AIDS-associated prurigo nodularis with thalidomide | 4 | 5 |
692 | 2 | 5 | 692 1998 CLINICAL INFECTIOUS DISEASES 26(1):184-185 Gori A; Franzetti F; Marchetti G; Rossi C; Fusi ML; Ruzzante S; Clerici M Clinical and immunological improvement in a patient who received thalidomide treatment for refractory Mycobacterium avium complex infection | 5 | 7 |
693 | 8 | 27 | 693 1998 CLINICAL PHARMACOLOGY & THERAPEUTICS 64(6):597-602 Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone | 13 | 15 |
694 | 22 | 80 | 694 1998 CURRENT MEDICINAL CHEMISTRY 5(3):163-178 Hashimoto Y Novel biological response modifiers derived from thalidomide | 16 | 38 |
695 | 9 | 10 | 695 1998 DRUG SAFETY 19(5):339-341 Smithells D Does thalidomide cause second generation birth defects? | 5 | 5 |
696 | 0 | 0 | 696 1998 EUROPEAN CYTOKINE NETWORK 9(3):367-367 Corral LG; Haslett PAJ; Ocampo C; Muller GW; Wong ML; Stirling D; Kaplan G Two distinct classes of thalidomide analogues which shape potent TNF-alpha inhibitory activity, modulate other cytokines differently | 0 | 0 |
697 | 29 | 60 | 697 1998 EXPERIMENTAL HEMATOLOGY 26(3):217-221 Or R; Feferman R; Shoshan S Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs | 18 | 24 |
698 | 0 | 0 | 698 1998 FASEB JOURNAL 12(4):A262-A262 Rowland TL; McHugh SM; Ewan PW; Lachmann PJ; Dearman RJ; Kimber I Down-regulation of T-cell and non-T-cell derived tumor necrosis factor alpha by thalidomide and dexamethasone | 0 | 0 |
699 | 0 | 0 | 699 1998 GASTROENTEROLOGY 114(4):A1008-A1008 Kenet G; Avni Y; Aeed H; Shirin H; Matas Z; Zaidel L; Galor S; Hershkovitz R; Bruck R Iodoacetamide-induced colitis in rats is inhibited by thalidomide. | 0 | 0 |
700 | 0 | 0 | 700 1998 GEBURTSHILFE UND FRAUENHEILKUNDE 58(3):M55-M58 Kosenow W Forty years ago: Thalidomide and its consequences | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
701 | 13 | 27 | 701 1998 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 236(6):461-466 Kruse FE; Joussen AM; Rohrschneider K; Becker MD; Volcker HE Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | 39 | 57 |
702 | 0 | 0 | 702 1998 HEPATOLOGY 28(4):460A-460A Martinez L; Lopez-Talavera JC; Martinez M; Cadelina G; Pachon JC; Esteban R; Guardia J; Groszmann RJ Amelioration of the hyperdynamic syndrome of cirrhotic rats by thalidomide. | 0 | 0 |
703 | 19 | 33 | 703 1998 IMMUNOPHARMACOLOGY 40(1):11-20 Rowland TL; McHugh SM; Deighton J; Dearman RJ; Ewan PW; Kimber I Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells | 36 | 48 |
704 | 2 | 25 | 704 1998 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 116(1):60-66 Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment | 9 | 13 |
705 | 5 | 14 | 705 1998 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 66(1):61-65 Moreira AL; Kaplan G; Villahermosa LG; Fajardo TJ; Abalos RM; Cellona RV; Balagon MVF; Tan EV; Walsh GP Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL | 1 | 9 |
706 | 6 | 28 | 706 1998 INTERNATIONAL JOURNAL OF STD & AIDS 9(12):751-755 Fife K; Howard MR; Gracie F; Phillips RH; Bower M Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre | 29 | 45 |
707 | 0 | 0 | 707 1998 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 280(10):872-872 Nightingale SL Thalidomide approved for erythema nodosum leprosum | 9 | 11 |
708 | 19 | 37 | 708 1998 JOURNAL OF EXPERIMENTAL MEDICINE 187(11):1885-1892 Haslett PAJ; Corral LG; Albert M; Kaplan G Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset | 144 | 179 |
709 | 14 | 30 | 709 1998 JOURNAL OF IMMUNOLOGY 161(8):4236-4243 Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production | 34 | 50 |
710 | 9 | 41 | 710 1998 JOURNAL OF INFECTIOUS DISEASES 177(6):1563-1572 Tsenova L; Sokol K; Freedman VH; Kaplan G Combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death | 14 | 26 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
711 | 0 | 0 | 711 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):516-516 Wolkenstein P; Latarget J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Milpied B; Bocquet H; Revuz J Randomized double-blind comparison of thalidomide versus placebo in toxic epidermal necrolysis: Overmortality in treated group. | 0 | 0 |
712 | 0 | 0 | 712 1998 JOURNAL OF INVESTIGATIVE DERMATOLOGY 110(4):693-693 Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse epidermal cell apoptosis by a TNF-alpha dependent pathway. | 0 | 0 |
713 | 10 | 15 | 713 1998 JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES 21(14):2151-2163 Haque A; Stewart JT Determination of racemic thalidomide in human plasma by use of an avidin column and solid phase extraction | 3 | 5 |
714 | 12 | 33 | 714 1998 JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 26(4):363-383 Hoglund P; Eriksson T; Bjorkman S A double-blind study of the sedative effects of the thalidomide enantiomers in humans | 11 | 15 |
715 | 16 | 27 | 715 1998 JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 24 | 25 |
716 | 10 | 33 | 716 1998 JOURNAL OF RHEUMATOLOGY 25(5):964-969 Oliver SJ; Cheng TP; Banquerigo ML; Brahn E The effect of thalidomide and 2 analogs on collagen induced arthritis | 16 | 32 |
717 | 9 | 14 | 717 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 38(3):490-491 Hecker MS; Lebwohl MG Recalcitrant pyoderma gangrenosum: Treatment with thalidomide | 14 | 21 |
718 | 7 | 10 | 718 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(2):293-295 Warren KJ; Nopper AJ; Crosby DL Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus | 7 | 9 |
719 | 10 | 18 | 719 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(5):835-838 Lee JB; Koblenzer PS Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report | 14 | 29 |
720 | 0 | 0 | 720 1998 JOURNAL OF VASCULAR RESEARCH 35:54-54 Baatz H; Tonnessen B; Pleyer U; Hartmann C Antiinflammatory action of thalidomide: Modulation of leukocyte-endothelium interaction | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
721 | 0 | 30 | 721 1998 LANCET 351(9110):1197-1199 Dally A Thalidomide: was the tragedy preventable? | 6 | 16 |
722 | 1 | 5 | 722 1998 LANCET 351(9115):1591-1591 Smithells D Was the thalidomide tragedy preventable? | 0 | 0 |
723 | 1 | 5 | 723 1998 LANCET 351(9115):1591-1591 Critchley EMR Was the thalidomide tragedy preventable? | 0 | 0 |
724 | 0 | 0 | 724 1998 LANCET 352(9124):298-298 Ault A Thalidomide makes a return to US health care | 0 | 0 |
725 | 5 | 5 | 725 1998 LANCET 352(9127):544-545 Stambe C; Wicks IP TNF alpha and response of treatment-resistant adult-onset Still's disease to thalidomide | 10 | 25 |
726 | 8 | 28 | 726 1998 LANCET 352(9140):1586-1589 Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis | 39 | 79 |
727 | 13 | 66 | 727 1998 MEDICAL HYPOTHESES 50(4):313-318 Argiles JM; Carbo N; Lopez-Soriano FJ Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? | 11 | 12 |
728 | 0 | 0 | 728 1998 MEDICAL LETTER ON DRUGS AND THERAPEUTICS 40(1038):103-104 [Anon] Thalidomide | 1 | 0 |
729 | 2 | 19 | 729 1998 METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 20(9):739-742 Guinan P; Shaw M; Mirochnik Y; Slobodskoy L; Ray V; Rubenstein M Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model | 2 | 5 |
730 | 0 | 0 | 730 1998 MOLECULAR BIOLOGY OF THE CELL 9:200A-200A Wilson K; Lancaster T; Boyd M; Taylor LD Inhibition of cell-cell contacts in T lymphoblastic cells during exposure to thalidomide. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
731 | 2 | 9 | 731 1998 NATURE 396(6709):322-323 Tabin CJ A developmental model for thalidomide defects | 9 | 21 |
732 | 0 | 0 | 732 1998 NATURE BIOTECHNOLOGY 16(8):695-695 [Anon] The problem with thalidomide's new incarnation | 0 | 0 |
733 | 0 | 0 | 733 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 357(4):R119-R119 Thiel R; Klug S Adhesion receptors on rat limb bud cells after treatment with a thalidomide derivative | 0 | 0 |
734 | 0 | 0 | 734 1998 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 358(1):R479-R479 Bignone IM; Papale RM; Seoane M; Bazerque PM Thalidomide - New trends for therapeutical use | 0 | 0 |
735 | 0 | 0 | 735 1998 NEUROLOGY 50(4):A208-A208 Poncelet AN; Maurer TA; Wu ZQ; Ng J; Badger J; Berger TG Peripheral neuropathy in HIV-infected patients with prurigo nodularis treated with thalidomide: Clinical and electrophysiologic features | 0 | 0 |
736 | 0 | 0 | 736 1998 NEUROLOGY 50(4):A383-A384 Frennier JM; Abrey LE; Haimovitz-Friedman A; McLoughlin M; Rosenfeld MR Does thalidomide have a role in glioma angiogenesis? | 0 | 0 |
737 | 10 | 55 | 737 1998 PAIN 74(1):83-91 Sommer C; Marziniak M; Myers RR The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve | 5 | 55 |
738 | 2 | 4 | 738 1998 PALLIATIVE MEDICINE 12(3):208-209 Deaner P Thalidomide for distressing night sweats in advanced malignant disease | 12 | 13 |
739 | 8 | 11 | 739 1998 REVUE DE MEDECINE INTERNE 19(3):196-198 Lair G; Marie I; Cailleux N; Blot E; Boullie MC; Courville P; Lauret P; Levesque H; Courtois H Langerhans cell histiocytosis in adult patients: cutaneous and mucous localizations improving with thalidomide | 9 | 13 |
740 | 3 | 5 | 740 1998 REVUE DE MEDECINE INTERNE 19(3):208-209 Grasland A; Pouchot J; Chaumaiziere D; Aitken G; Vinceneux P Effectiveness of thalidomide in cutaneous sarcoidosis | 3 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
741 | 15 | 33 | 741 1998 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 48(4):397-402 Zhu J; Deng GM; Diab A; Zwingenberger K; Bakhiet M; Link H Thalidomide prolongs experimental autoimmune neuritis in Lewis rats | 4 | 10 |
742 | 66 | 87 | 742 1998 SEMINARS IN CUTANEOUS MEDICINE AND SURGERY 17(4):231-242 Stirling DI Thalidomide and its impact in dermatology | 14 | 17 |
743 | 0 | 0 | 743 1999 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 217:U88-U88 Konnecke WE; Smith AM; Khetani VD A two step synthesis of thalidomide. | 0 | 0 |
744 | 0 | 0 | 744 1999 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 218:U58-U58 Luzzio FA; Thomas EM; Figg WD Stereoselective synthesis of thalidomide analogs. | 0 | 0 |
745 | 22 | 30 | 745 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(12):1047-1052 Noormohamed FH; Youle MS; Higgs CJ; Kook KA; Hawkins DA; Lant AF; Thomas SD Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects | 13 | 13 |
746 | 12 | 39 | 746 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(13):1169-1179 Haslett PAJ; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients | 27 | 33 |
747 | 1 | 1 | 747 1999 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 56(17):1721-1725 Keravich DP; Daniels CE Challenges of thalidomide distribution in a hospital setting | 0 | 0 |
748 | 6 | 24 | 748 1999 AMERICAN JOURNAL OF PUBLIC HEALTH 89(1):98-101 Annas GJ; Elias S Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century | 5 | 7 |
749 | 0 | 0 | 749 1999 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 159(3):A271-A271 Lindsay L; Oliver S; Freeman S; Regis J; Krauss A; Kaplan G The role of thalidomide and steroid in modulating the expression of TNF-alpha (TNA-a) and IL-6 in the hyperoxic newborn rat lung. | 0 | 0 |
750 | 6 | 12 | 750 1999 ANNALS OF ONCOLOGY 10(7):857-859 Bruera E; Neumann CM; Pituskin E; Calder K; Ball G; Hanson J Thalidomide in patients with cachexia due to terminal cancer: Preliminary report | 15 | 31 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
751 | 29 | 79 | 751 1999 ANNALS OF THE RHEUMATIC DISEASES 58:107-113 Corral LG; Kaplan G Immunomodulation by thalidomide and thalidomide analogues | 13 | 18 |
752 | 11 | 23 | 752 1999 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 43(9):2305-2306 Ridoux O; Drancourt M Lack of in vitro antimicrosporidian activity of thalidomide | 1 | 1 |
753 | 30 | 53 | 753 1999 ARCHIVES OF DERMATOLOGY 135(9):1079-1087 Duong DJ; Spigel GT; Moxley RT; Gaspari AA American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus | 20 | 29 |
754 | 3 | 8 | 754 1999 ARTHRITIS AND RHEUMATISM 42(3):580-581 Breban M; Gombert B; Amor B; Dougados M Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis | 16 | 53 |
755 | 0 | 0 | 755 1999 ARTHRITIS AND RHEUMATISM 42(9):S91-S91 Connolly JE; Rigby WFC Thalidomide inhibits LPS induced activation of p38 and JNK stress activated kinase pathways. | 0 | 0 |
756 | 0 | 0 | 756 1999 ARTHRITIS AND RHEUMATISM 42(9):S187-S187 Oliver SJ; Moreira A; Kaplan G Reduced fibrosis and normalization of skin structure in scleroderma patients treated with thalidomide. | 1 | 5 |
757 | 0 | 0 | 757 1999 ARTHRITIS AND RHEUMATISM 42(9):S276-S276 Oliver SJ; Moreira A; Ozawa M; Krueger JG; Kaplan G Beneficial effects of thalidomide in sarcoidosis are associated with an enhanced Th1-type immune response | 0 | 0 |
758 | 0 | 0 | 758 1999 ARTHRITIS AND RHEUMATISM 42(9):S373-S373 El Hassani S; Dougados M; Gombert B; Amor B; Breban M Treatment of severe retractory spondylarthopathy (SPA) with thalidomide: Results of an open study. | 2 | 6 |
759 | 0 | 0 | 759 1999 ARTHRITIS AND RHEUMATISM 42(10):2259-2260 Gompel A; Frances C; Piette JC; Blanc AS; Cordoliani F; Piette AM Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al | 8 | 9 |
760 | 0 | 0 | 760 1999 ARTHRITIS AND RHEUMATISM 42(10):2260-2260 Ordi J; Cortes F; Balada E; Mauri M; Vilardell M Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al - Reply | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
761 | 48 | 79 | 761 1999 BIODRUGS 11(6):409-416 Powell RJ Thalidomide - Current uses | 1 | 2 |
762 | 8 | 26 | 762 1999 BIOLOGICAL & PHARMACEUTICAL BULLETIN 22(2):224-226 Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide | 11 | 17 |
763 | 0 | 0 | 763 1999 BLOOD 94(10):124A-124A Neben K; Hawighorst H; Moehler TM; Egerer G; Punzel M; Van Kaick G; Ho AD; Goldschmidt H Clinical response to thalidomide monotherapy correlates with improvement in dynamic magnetic resonance (d-MRI) angiogenesis parameters. | 0 | 9 |
764 | 0 | 0 | 764 1999 BLOOD 94(10):124A-124A Juliusson G; Celsing F; Turesson I; Adriansson M; Malm C Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant. | 0 | 2 |
765 | 0 | 0 | 765 1999 BLOOD 94(10):124A-125A Moehler TM; Neben K; Egerer G; Punzel M; Schmier J; Cremer F; Goldschmidt H; Ho AD Thalidomide plus CED-chemotherapy in patients with poor prognosis multiple myeloma. | 0 | 0 |
766 | 0 | 0 | 766 1999 BLOOD 94(10):125A-125A Sabir T; Raza S; Anderson L; Jagannath S Thalidomide is effective in the treatment of recurrent. Refractory multiple myeloma (MM). | 0 | 7 |
767 | 0 | 0 | 767 1999 BLOOD 94(10):125A-125A Shima Y; Treon SP; Yoshizaki K; Tai YT; Hideshima T; Raje N; Chauhan D; Davies F; Schlossman R; Anderson KC Clinical and biological activity of thalidomide (Thal) in multiple myeloma (MM). | 0 | 11 |
768 | 0 | 0 | 768 1999 BLOOD 94(10):158A-158A Koc S; Leisenring W; Flowers ME; Sullivan KM; Martin PJ Evaluation of thalidomide for the treatment of chronic graft-versus-host disease in "high risk" patients. | 0 | 1 |
769 | 0 | 0 | 769 1999 BLOOD 94(10):308B-308B Chen CI; Adesanya A; Sutton DM; Brandwein J; Stewart AK Low-dose thalidomide in patients with advanced, refractory multiple myeloma. | 0 | 1 |
770 | 0 | 0 | 770 1999 BLOOD 94(10):308B-308B Coleman M; Gelfand RM; Leonard JP Combination non-myelosuppressive therapy (thalidomide, clarithromycin, dexamethasone) for plasma cell myeloma: A preliminary report. | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
771 | 0 | 0 | 771 1999 BLOOD 94(10):311B-311B Kanard AM; Kane G; Thome SD; Goudreau J; Markovic SN Thalidomide associated with seizures and neuroradiologic features suggestive of reversible posterior leukoencephalopathy syndrome (RPLS) in the setting of multiple myeloma and renal failure. | 0 | 1 |
772 | 0 | 0 | 772 1999 BLOOD 94(10):314B-315B Srkalovic G; Karam MA; McLain DA; Hussein MA Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM). | 0 | 1 |
773 | 0 | 0 | 773 1999 BLOOD 94(10):315A-315A Cheng D; Kini AR; Rodriguez J; Burt RK; Peterson LC; Traynor AE Microvascular density and cytotoxic T cell activation correlate with response to thalidomide therapy in myeloma patients. | 0 | 8 |
774 | 0 | 0 | 774 1999 BLOOD 94(10):316B-316B Wu K; Schaafsma MR; Smit WM; Neef C; Richel DJ Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM). | 0 | 1 |
775 | 0 | 0 | 775 1999 BLOOD 94(10):316A-316A Durie BGM; Stepan DE Efficacy of low dose thalidomide (T) in multiple myeloma. | 0 | 18 |
776 | 0 | 0 | 776 1999 BLOOD 94(10):316A-316A Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed and refractory myeloma. | 0 | 9 |
777 | 0 | 0 | 777 1999 BLOOD 94(10):317A-317A Yaccoby S; Johnson CL; Mahaffey SC; Barlogie B; Epstein J Thalidomide metabolism and its anti-myeloma efficacy in vivo. | 0 | 1 |
778 | 0 | 0 | 778 1999 BLOOD 94(10):317A-317A Schiller G; Vescio R; Berenson J Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant. | 0 | 8 |
779 | 0 | 0 | 779 1999 BLOOD 94(10):507A-507A Thomas DA; Aguayo A; Estey E; Albitar M; O'Brien S; Giles FJ; Beran M; Cortes J; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide as anti-angiogenesis therapy (RX) in refractory or relapsed leukemias. | 0 | 5 |
780 | 0 | 0 | 780 1999 BLOOD 94(10):578A-578A Munshi N; Desikan R; Anaissie E; Zangari M; Badros A; Lim S; Toor A; Morris C; Eddlemon P; Ayers D; Roberson P; Barlogie B Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF as part of Total Therapy II in newly diagnosed multiple myeloma (MM): Influence of thalidomide (THAL) administration. | 0 | 7 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
781 | 0 | 0 | 781 1999 BLOOD 94(10):603A-603A Desikan R; Munshi N; Zeldis J; Eddlemon P; Badros A; Zangari M; Singhal S; Mehta J; Ayers D; Lim S; Wilson C; Anaissie E; Crowley J; Barlogie B Activity of thalidomide (THAL) in multiple myeloma (MM) confirmed in 180 patients with advanced disease. | 0 | 3 |
782 | 0 | 0 | 782 1999 BLOOD 94(10):604A-604A Weber DM; Gavino M; Delasalle K; Rankin K; Giralt S; Alexanian R Thalidomide alone or with dexamethasone for multiple myeloma. | 0 | 27 |
783 | 0 | 0 | 783 1999 BLOOD 94(10):661A-661A Raza A; Lisak L; Andrews C; Little L; Muzammil M; Alvi S; Mazzoran L; Zorat F; Akber A; Ekbal M; Razvi S; Venugopal P Thalidomide produces transfusion independence in patients with long-standing refractory anemias and myelodysplastic syndromes (MDS). | 0 | 9 |
784 | 0 | 0 | 784 1999 BLOOD 94(10):702A-702A Thomas DA; Aguayo A; Giles FJ; Albitar M; O'Brien S; Cortes J; Faderl S; Bivins C; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). | 0 | 15 |
785 | 4 | 42 | 785 1999 BRITISH JOURNAL OF CANCER 79(1):114-118 Verheul HMW; Panigrahy D; Yuan J; D'Amato RJ Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits | 17 | 33 |
786 | 20 | 42 | 786 1999 BRITISH JOURNAL OF CANCER 80(5-6):716-723 Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid | 11 | 26 |
787 | 22 | 35 | 787 1999 CANCER CHEMOTHERAPY AND PHARMACOLOGY 43:S78-S84 Dixon SC; Kruger EA; Bauer KS; Figg WD Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells | 8 | 14 |
788 | 9 | 51 | 788 1999 CELLULAR AND MOLECULAR BIOLOGY 45(5):579-588 Gaffield W; Incardona JP; Kapur RP; Roelink H A looking glass perspective: Thalidomide and cyclopamine | 0 | 6 |
789 | 13 | 16 | 789 1999 CLEVELAND CLINIC JOURNAL OF MEDICINE 66(3):136-+ Calabrese LH Thalidomide's tightly controlled "comeback" | 3 | 3 |
790 | 9 | 31 | 790 1999 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 118(2):315-321 Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis | 9 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
791 | 4 | 5 | 791 1999 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 17(3):393-393 de Wazieres B; Gil H; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low doses of thalidomide | 2 | 3 |
792 | 4 | 10 | 792 1999 CLINICAL INFECTIOUS DISEASES 28(4):892-894 Ramirez-Amador VA; Esquivel-Pedraza L; Ponce-de-Leon S; Reyes-Teran G; Gonzalez-Guevara M; Ponce-de-Leon S; Sierra-Madero JG Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: A double-blind placebo-controlled clinical trial | 4 | 5 |
793 | 6 | 11 | 793 1999 CLINICAL NEUROPHYSIOLOGY 110(4):735-739 Sadoh DR; Hawk JLM; Panayiotopoulos CP F-chronodispersion in patients on thalidomide | 5 | 5 |
794 | 8 | 27 | 794 1999 CLINICAL PHARMACOLOGY & THERAPEUTICS 65(5):483-490 Scheffler MR; Colburn W; Kook KA; Thomas SD Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics | 12 | 12 |
795 | 0 | 1 | 795 1999 CLINICAL REHABILITATION 13(3):250-252 Newman RJ Shoulder joint replacement for osteoarthrosis in association with thalidomide-induced phocomelia | 0 | 0 |
796 | 1 | 17 | 796 1999 CLINICAL THERAPEUTICS 21(2):319-330 Zeldis JB; Williams BA; Thomas SD; Elsayed ME STEPS (TM): A comprehensive program for controlling and monitoring access to thalidomide | 39 | 47 |
797 | 3 | 44 | 797 1999 CURRENT EYE RESEARCH 19(6):483-490 Spraul CW; Kaven C; Kampmeier J; Lang GK; Lang GE Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro | 5 | 9 |
798 | 2 | 5 | 798 1999 DERMATOLOGY 199(2):195-195 Bez C; Lodi G; Sardella A; Della Volpe A; Carrassi A Oral lichenoid lesions after thalidomide treatment | 5 | 5 |
799 | 9 | 23 | 799 1999 DRUG SAFETY 21(3):161-169 Lary JM; Daniel KL; Erickson JD; Roberts HE; Moore CA The return of thalidomide - Can birth defects be prevented? | 5 | 10 |
800 | 12 | 70 | 800 1999 DRUGS 58(6):953-963 Ravot E; Lisziewicz J; Lori F New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide | 3 | 15 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
801 | 12 | 34 | 801 1999 ELECTROPHORESIS 20(12):2425-2431 Meyring M; Chankvetadze B; Blaschke G Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives | 2 | 13 |
802 | 19 | 36 | 802 1999 ETHIOPIAN MEDICAL JOURNAL 37(4):275-280 Shannon EJ 24th Kellersberger Memorial Lecture, 1999 thalidomide: Will the past overshadow a promising future? | 0 | 0 |
803 | 0 | 0 | 803 1999 GASTROENTEROLOGY 116(4):A745-A745 Kane SV; Ehrenpreis ED; Cohen LB; Hanauer SB; Cohen RD Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD) | 2 | 5 |
804 | 0 | 0 | 804 1999 GASTROENTEROLOGY 116(4):A767-A767 Macumber C; Wettstein AP; Vickers CR; Hing M; Edwards PD; Byrnes DJ; Meagher AP Thalidomide-effective therapy in chronic resistant inflammatory bowel disease. Department of gastroenterology. St. Vincent's Hospital, Sydney, Australia. | 2 | 3 |
805 | 0 | 0 | 805 1999 GASTROENTEROLOGY 116(4):A837-A837 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Papadakis KA; Zeldis JB; Targan SR An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-department Crohn's disease (CD) | 3 | 0 |
806 | 0 | 0 | 806 1999 GASTROENTEROLOGY 116(4):A843-A843 Wedel S; Bauditz J; Suk A; Lochs H Efficacy of thalidomide in Crohn's disease. | 2 | 3 |
807 | 20 | 33 | 807 1999 GASTROENTEROLOGY 117(6):1271-1277 Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 44 | 132 |
808 | 16 | 40 | 808 1999 GASTROENTEROLOGY 117(6):1278-1287 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Hassard PV; Papadakis KA; Yang HY; Zeldis JB; Targan SR An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease | 43 | 129 |
809 | 22 | 32 | 809 1999 GASTROENTEROLOGY 117(6):1485-1488 Sands BE; Podolsky DK New life in a sleeper: Thalidomide and Crohn's disease | 8 | 25 |
810 | 7 | 33 | 810 1999 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 237(12):952-961 Joussen AM; Germann T; Kirchhof B Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency | 4 | 8 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
811 | 5 | 12 | 811 1999 GUT 45(3):463-464 Ollivier S; Bonnet J; Lemann M; Coffin JC; Modigliani R; Jian R; Bertheau P; Flejou JF Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment | 1 | 2 |
812 | 15 | 32 | 812 1999 IMMUNOLOGY LETTERS 68(2-3):325-332 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone | 10 | 13 |
813 | 38 | 52 | 813 1999 IMMUNOLOGY TODAY 20(12):538-540 Marriott JB; Muller G; Dalgleish AG Thalidomide as an emerging immunotherapeutic agent | 38 | 47 |
814 | 5 | 17 | 814 1999 IMMUNOPHARMACOLOGY 43(1):59-64 Dunzendorfer S; Herold M; Wiedermann CJ Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide | 8 | 8 |
815 | 2 | 29 | 815 1999 INFLAMMATION 23(6):495-505 Gallily R; Kipper-Galperin M; Brenner T Mycoplasma fermentans-induced inflammatory response of astrocytes: Selective modulation by aminoguanidine, thalidomide, pentoxifylline and IL-10 | 1 | 4 |
816 | 6 | 10 | 816 1999 INTERNATIONAL JOURNAL OF DERMATOLOGY 38(1):76-77 Pizarro A; Garcia-Tobaruela A; Herranz P; Pinilla J Thalidomide as an inhibitor of tumor necrosis factor-alpha production: a word of caution | 1 | 1 |
817 | 4 | 24 | 817 1999 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 80(1):11-16 Arrieta O; Ortiz-Reyes A; Rembao D; Calvillo M; Rivera E; Sotelo J Protective effect of pentoxifylline plus thalidomide against septic shock in mice | 4 | 8 |
818 | 9 | 29 | 818 1999 INTERNATIONAL JOURNAL OF TOXICOLOGY 18(5):337-352 Teo SK; Trigg NJ; Shaw ME; Morgan JM; Thomas SD Subchronic toxicity of thalidomide in rodents after 13 weeks of oral administration | 7 | 7 |
819 | 0 | 0 | 819 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S84-S84 Velez G; Robinson MR; Durbin T; Yuan P; Sung C; Whitcup SM Thalidomide-sustained release devices for choroidal neovascularization; An in-vitro analysis | 0 | 1 |
820 | 0 | 0 | 820 1999 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40(4):S224-S224 Spraul CW; Kaven C; Amann J; Lang GK; Lang GE Effect of thalidomide, octreotide, and decortine on the migration and proliferation of RPE cells in vitro | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
821 | 12 | 27 | 821 1999 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 5(5):261-267 Scoville CD; Reading JC Open trial of thalidomide in the treatment of rheumatoid arthritis | 1 | 1 |
822 | 0 | 0 | 822 1999 JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 103(1):S20-S20 Martinez A; Hernandez T; Hernandez V; Espinosa F Thalidomide for pertinacious vasculitic syndrome secondary to coxsackie A virus infection. | 0 | 0 |
823 | 4 | 52 | 823 1999 JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME 81B(1):9-23 McCredie J; Willert HG Longitudinal limb deficiencies and the sclerotomes - An analysis of 378 dysmelic malformations induced by thalidomide | 0 | 8 |
824 | 8 | 18 | 824 1999 JOURNAL OF CHROMATOGRAPHY B 723(1-2):255-264 Meyring M; Strickmann D; Chankvetadze B; Blaschke G; Desiderio C; Fanali S Investigation of the in vitro biotransformation of R-(+)- thalidomide by HPLC, nano-HPLC, CEC and HPLC-APCI-MS | 8 | 20 |
825 | 9 | 9 | 825 1999 JOURNAL OF CHROMATOGRAPHY B 734(2):203-210 Torano JS; Verbon A; Guchelaar HJ Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection | 8 | 8 |
826 | 8 | 15 | 826 1999 JOURNAL OF CLINICAL PHARMACOLOGY 39(11):1162-1168 Teo SK; Colburn WA; Thomas SD Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers | 19 | 19 |
827 | 10 | 48 | 827 1999 JOURNAL OF IMMUNOLOGY 163(1):380-386 Corral LG; Haslett PAJ; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | 80 | 127 |
828 | 6 | 17 | 828 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):61-67 Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N; Natl Inst Allergy Infect Dis AIDS Clin Trials G Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection | 27 | 38 |
829 | 6 | 15 | 829 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):216-219 Meierhofer C; Dunzendorfer S; Wiederman CJ Protein kinase C-dependent effects on leukocyte migration of thalidomide | 5 | 10 |
830 | 25 | 52 | 830 1999 JOURNAL OF INVESTIGATIVE DERMATOLOGY 113(5):720-724 Nasca MR; O'Toole EA; Palicharla P; West DP; Woodley DT Thalidomide increases human keratinocyte migration and proliferation | 6 | 15 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
831 | 9 | 28 | 831 1999 JOURNAL OF NEURO-ONCOLOGY 43(2):109-114 Moreira AL; Friedlander DR; Shif B; Kaplan G; Zagzag D Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro | 22 | 37 |
832 | 6 | 32 | 832 1999 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 15(5):429-438 Siefert B; Pleyer U; Muller M; Hartmann C; Keipert S Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide | 0 | 10 |
833 | 12 | 23 | 833 1999 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 28(2):214-216 Weinstein TA; Sciubba JJ; Levine J Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease | 10 | 21 |
834 | 16 | 28 | 834 1999 JOURNAL OF PHARMACEUTICAL SCIENCES 88(1):121-125 Figg WD; Raje S; Bauer KS; Tompkins A; Venzon D; Bergan R; Chen A; Hamilton M; Pluda J; Reed E Pharmacokinetics of thalidomide in an elderly prostate cancer population | 34 | 48 |
835 | 10 | 15 | 835 1999 JOURNAL OF RHEUMATOLOGY 26(11):2344-2347 Keesal N; Wasserman MJ; Bookman A; Lapp V; Weber DA; Keystone EC Thalidomide in the treatment of refractory rheumatoid arthritis | 14 | 18 |
836 | 6 | 23 | 836 1999 JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN 57(2):92-104 Shimazawa R; Takayama H; Hashimoto Y Development of novel biological response modifiers derived from thalidomide | 0 | 7 |
837 | 4 | 5 | 837 1999 LANCET 353(9149):324-324 Klausner JD; Kaplan G; Haslett PAJ Thalidomide in toxic epidermal necrolysis | 7 | 8 |
838 | 1 | 2 | 838 1999 LANCET 353(9149):324-324 Levy R Thalidomide in toxic epidermal necrolysis | 1 | 2 |
839 | 1 | 1 | 839 1999 LANCET 353(9163):1503-1503 Moore P Thalidomide's teratogenic mechanism starts to yield to study | 0 | 0 |
840 | 0 | 0 | 840 1999 LANCET 354(9182):925-925 Larkin M Low-dose thalidomide seems to be effective in multiple myeloma | 9 | 14 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
841 | 0 | 0 | 841 1999 LANCET 354(9191):1705-1705 Larkin M Thalidomide continues to look promising as an anticancer agent | 1 | 1 |
842 | 3 | 10 | 842 1999 LUPUS 8(3):248-249 Rua-Figueroa I; Erausquin C; Naranjo A; Carretero-Hernandez G; Rodriguez-Lozano C; De la Rosa P Pustuloderma during cutaneous lupus treatment with thalidomide | 3 | 5 |
843 | 3 | 14 | 843 1999 MEDICAL HYPOTHESES 53(1):76-77 Sastry PSRK Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis | 5 | 7 |
844 | 0 | 0 | 844 1999 MOLECULAR BIOLOGY OF THE CELL 10:75A-75A Taylor LD; Settles B; Wilson K; Mack C Investigation of the inhibition of cell adhesion by the Anti-TNF-alpha agent thalidomide utilizing in vitro fluorescence-based assays. | 0 | 0 |
845 | 23 | 79 | 845 1999 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 425(1):153-167 Zhu XY; Zhang YP; Klopman G; Rosenkranz HS Thalidomide and metabolites: indications of the absence of 'genotoxic' carcinogenic potentials | 3 | 3 |
846 | 4 | 11 | 846 1999 NATURE 400(6743):419-420 Neubert R; Merker HT; Neubert D Developmental model for thalidomide action | 3 | 4 |
847 | 2 | 12 | 847 1999 NATURE 400(6743):420-420 Tabin CJ Developmental model for thalidomide action - Reply | 0 | 0 |
848 | 5 | 11 | 848 1999 NATURE MEDICINE 5(5):489-490 Hales BF Thalidomide on the comeback trail | 30 | 32 |
849 | 10 | 25 | 849 1999 NATURE MEDICINE 5(5):582-585 Parman T; Wiley MJ; Wells PG Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | 65 | 111 |
850 | 1 | 3 | 850 1999 NATURE MEDICINE 5(8):853-853 Guenzler V Mechanisms of thalidomide teratogenicity | 2 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
851 | 0 | 0 | 851 1999 NEUROLOGY 52(6):A424-A425 Li HW; Zhu LX; Karpati G; Nalbantoglu J Effect of thalidomide on growth of experimental intracerebral gliomas | 0 | 0 |
852 | 9 | 37 | 852 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1565-1571 Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeldis J; Barlogie B; Siegel D; Crowley J Antitumor activity of thalidomide in refractory multiple myeloma. | 293 | 558 |
853 | 8 | 17 | 853 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1606-1609 Raje N; Anderson K Thalidomide - A revival story. | 48 | 87 |
854 | 0 | 0 | 854 1999 ONCOLOGY-NEW YORK 13(5):744-744 [Anon] Thalidomide shows promising results in patients with multiple myeloma | 0 | 0 |
855 | 16 | 39 | 855 1999 ORGANIC LETTERS 1(10):1571-1573 Takeuchi Y; Shiragami T; Kimura K; Suzuki E; Shibata N (R)- and (S)-3-fluorothalidomides: Isosteric analogues of thalidomide | 3 | 14 |
856 | 3 | 13 | 856 1999 ORGANIC PROCESS RESEARCH & DEVELOPMENT 3(2):139-140 Muller GW; Konnecke WE; Smith AM; Khetani VD A concise two-step synthesis of thalidomide | 5 | 12 |
857 | 0 | 0 | 857 1999 PEDIATRIC RESEARCH 45(4):67A-67A Jakkula M; Le Cras TD; Abman SH Effects of fumagillin and thalidomide treatment on alveolarization in the developing rat lung | 0 | 4 |
858 | 11 | 13 | 858 1999 PEDIATRICS 103(4):art. no.-e44 Mehta P; Kedar A; Graham-Pole J; Skoda-Smith S; Wingard JR Thalidomide in children undergoing bone marrow transplantation: Series at a single institution and review of the literature | 0 | 10 |
859 | 10 | 22 | 859 1999 PEDIATRICS 103(6):1295-1297 Shek LPC; Lee YS; Lee BW; Lehman TJA Thalidomide responsiveness in an infant with Behcet's syndrome | 10 | 16 |
860 | 3 | 8 | 860 1999 PHARMACOLOGY & TOXICOLOGY 85(2):103-104 Huang PHT; McBride WG; Tuman WG Interaction of thalidomide with DNA of rabbit embryos: A possible explanation for its immunosuppressant and teratogenic effects | 3 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
861 | 11 | 22 | 861 1999 PHARMACOTHERAPY 19(10):1177-1180 Horowitz SB; Stirling AL Thalidomide-induced toxic epidermal necrolysis | 10 | 10 |
862 | 8 | 40 | 862 1999 REPRODUCTIVE TOXICOLOGY 13(6):547-554 Hansen JM; Carney EW; Harris C Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro | 6 | 11 |
863 | 12 | 17 | 863 1999 REVUE DE MEDECINE INTERNE 20(7):567-570 de Wazieres B; Gil H; Magy N; Berthier S; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low dose of thalidomide. Pilot study in 17 patients | 3 | 9 |
864 | 13 | 35 | 864 1999 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):305-311 Monastirli A; Georgiou S; Bolsen K; Pasmatzi E; Papapanagiotou A; Goerz G; Kalofoutis A; Merk HF; Tsambaos D Treatment of porphyria cutanea tarda with oral thalidomide | 5 | 7 |
865 | 8 | 30 | 865 1999 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):312-316 Kalofoutis A; Monastirli A; Papapanagiotou A; Georgiou S; Pasmatzi E; Sakkis T; Bolsen K; Goerz G; Merk HF; Tsambaos D Alterations of rat liver phospholipid composition induced by oral thalidomide | 0 | 0 |
866 | 5 | 11 | 866 1999 SLEEP 22(1):113-115 Kanbayashi T; Shimizu T; Takahashi Y; Kitajima T; Takahashi K; Saito Y; Hishikawa Y Thalidomide increases both REM and stage 3-4 sleep in human adults: A preliminary study | 9 | 11 |
867 | 13 | 40 | 867 1999 SURGERY 125(5):536-544 Kotoh T; Dhar DK; Masunaga R; Tabara H; Tachibana M; Kubota H; Kohno H; Nagasue N Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice | 12 | 27 |
868 | 69 | 136 | 868 1999 TERATOLOGY 60(5):306-321 Miller MT; Stromland K Teratogen update: Thalidomide: A review, with a focus on ocular findings and new potential uses | 7 | 19 |
869 | 0 | 0 | 869 2000 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 219:U227-U227 Luzzio FA; Mayorov AV; Figg WD Thalidomide metabolites: Preparation of (+)-2-(N-phthalimido)- 4-hydroxyglutamic acid derivatives. | 0 | 0 |
870 | 0 | 0 | 870 2000 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 220:U96-U96 Luzzio FA; Thomas EM; Figg WD Thalidomide analogs and metabolites: Cyclic and acyclic derivatives of 2S, 3S-2-N-phthalimido(3-hydroxy)ornithine. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
871 | 3 | 9 | 871 2000 ACTA DERMATO-VENEREOLOGICA 80(1):24-25 Daly BM; Shuster S Antipruritic action of thalidomide | 3 | 9 |
872 | 5 | 5 | 872 2000 AIDS 14(12):1859-1861 Gori A; Rossi MC; Marchetti G; Trabattoni D; Molteni C; Cogliati M; Bandera A; Clerici M; Franzetti F Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease | 5 | 7 |
873 | 13 | 32 | 873 2000 AIDS RESEARCH AND HUMAN RETROVIRUSES 16(14):1345-1355 Kaplan G; Thomas S; Fierer DS; Mulligan K; Haslett PAJ; Fessel WJ; Smith LG; Kook KA; Stirling D; Schambelan M Thalidomide for the treatment of AIDS-associated wasting | 13 | 28 |
874 | 3 | 14 | 874 2000 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 23(3):319-321 Patt YZ; Hassan MM; Lozano RD; Ellis LM; Peterson JA; Waugh KA Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide | 14 | 26 |
875 | 7 | 12 | 875 2000 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 57(17):1607-1610 Eriksson T; Wallin R; Hoglund P; Roth B; Qi ZQ; Ostraat O; Bjorkman S Low bioavailability of rectally administered thalidomide | 2 | 2 |
876 | 0 | 0 | 876 2000 AMERICAN JOURNAL OF HUMAN GENETICS 67(4):134-134 Nippert I 40 years later: The health related quality of life of women affected by Thalidomide. | 0 | 0 |
877 | 62 | 96 | 877 2000 AMERICAN JOURNAL OF MEDICINE 108(6):487-495 Calabrese L; Fleischer AB Thalidomide: Current and potential clinical applications | 60 | 103 |
878 | 9 | 60 | 878 2000 AMERICAN JOURNAL OF NEURORADIOLOGY 21(5):881-890 Cha S; Knopp EA; Johnson G; Litt A; Glass J; Gruber ML; Lu S; Zagzag D Dynamic contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin | 3 | 24 |
879 | 6 | 24 | 879 2000 AMERICAN JOURNAL OF PATHOLOGY 156(1):151-158 Sauer H; Gunther J; Hescheler J; Wartenberg M Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals | 16 | 33 |
880 | 8 | 20 | 880 2000 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(2):171-174 Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L Thalidomide and thrombosis. | 25 | 27 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
881 | 85 | 116 | 881 2000 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(6-7):603-613 Laffitte E; Revuz J Thalidomide | 7 | 9 |
882 | 0 | 0 | 882 2000 ANNALS OF ONCOLOGY 11:54-54 Martinelli G; Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F Clinical efficacy of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis | 0 | 0 |
883 | 0 | 0 | 883 2000 ANNALS OF ONCOLOGY 11:60-60 Gasparini G; Gilberti S; Vitale S; Arena MG; Fanelli M; Ranieri G; Gattuso D; Biondi E; Morabito A Antitumoral activity of Thalidomide in patients affected by refractory breast cancer nad recurrent high grade gliomas. | 0 | 0 |
884 | 0 | 0 | 884 2000 ANNALS OF ONCOLOGY 11:96-96 Galani E; Grigoraki V; Kiamouris C; Samantas E; Economou O; Papdimitriou C; Gika D; Anagnostopoulos N; Dimopoulos M Thalidomide and dexamethasone combination for refractory multiple myeloma. | 0 | 0 |
885 | 0 | 0 | 885 2000 ANNALS OF ONCOLOGY 11:96-96 Mingrone W; Alietti A; Ferrucci F; Cocorocchio E; Peccatori F; Cinieri S; Corsini C; Zucca E; Bertolini F; Martinelli G Clinical efficacy and biologic activity of thalidomide in multiple myeloma (MM), myelodysplastic syndromes (MDS) and histiocytosis. | 0 | 0 |
886 | 19 | 38 | 886 2000 ANTI-CANCER DRUGS 11(10):787-791 Adlard JW Thalidomide in the treatment of cancer | 5 | 11 |
887 | 17 | 32 | 887 2000 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 44(9):2286-2290 Verbon A; Juffermans NP; Speelman P; van Deventer SJH; ten Berge IJM; Guchelaar HJ; van der Poll T A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans | 17 | 18 |
888 | 4 | 4 | 888 2000 ARCHIVES OF DERMATOLOGY 136(12):1442-1443 Camisa C; Popovsky JL Effective treatment of oral erosive lichen planus with thalidomide | 6 | 11 |
889 | 3 | 5 | 889 2000 ARCHIVES OF OPHTHALMOLOGY 118(1):135-136 Periman LM; Sires BS Full-thickness skin grafting of eyelids in a patient with generalized morphea taking thalidomide | 1 | 1 |
890 | 6 | 20 | 890 2000 ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 126(1):89-92 Dios PD; Sopena B; Cameselle J; Butron M; Crespo M; Ocampo A Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers | 2 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
891 | 0 | 0 | 891 2000 ARTHRITIS AND RHEUMATISM 43(9):S117-S117 Lowe D; Kredich DW; Schanberg LE Thalidomide: An effective and safe agent for the treatment of pediatric mixed connective tissue disease. | 0 | 0 |
892 | 0 | 0 | 892 2000 ARTHRITIS AND RHEUMATISM 43(9):S396-S396 Huang F; Gu J; Braun J; Sieper J; Yu DT Identifying the targets of thalidomide and anti-TNF alpha antibody treatments in ankylosing spondylitis (AS). | 2 | 5 |
893 | 26 | 174 | 893 2000 BIOCHEMICAL PHARMACOLOGY 59(12):1489-1499 Stephens TD; Bunde CJW; Fillmore BJ Mechanism of action in thalidomide teratogenesis | 24 | 36 |
894 | 75 | 113 | 894 2000 BIODRUGS 13(4):255-265 Kontogiannis V; Powell RJ Use of thalidomide in dermatological indications | 0 | 0 |
895 | 13 | 33 | 895 2000 BIOPHARMACEUTICS & DRUG DISPOSITION 21(1):33-40 Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women | 6 | 6 |
896 | 10 | 31 | 896 2000 BLOOD 96(9):2943-2950 Hideshima T; Chauhan D; Shima Y; Raje N; Davies FE; Tai YT; Treon SP; Lin B; Schlossman RL; Richardson P; Muller G; Stirling DI; Anderson KC Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy | 90 | 173 |
897 | 0 | 0 | 897 2000 BLOOD 96(11):146A-146A Raza A; Lisak L; Little L; Ekbal M; du Rant M; Ali E; Nascimben F; Tareen M; Venugopal P Thalidomide as a single agent or in combination with topotecan, pentoxifylline and/or Enbrel in myelodysplastic syndromes (MDS). | 0 | 6 |
898 | 0 | 0 | 898 2000 BLOOD 96(11):146A-146A Mundle S; Zorat F; Shetty V; Allampallam K; Alvi S; Lisak L; Little L; Dean L; Nascimben F; Ekbal M; duRandt M; Broderick E; Venugopal P; Raza A Biologic determinents of clinical response to thalidomide in myelodysplasia. | 0 | 3 |
899 | 0 | 0 | 899 2000 BLOOD 96(11):167A-167A Yakoub-Agha I; Attal M; Dumontet C; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux I; Bay JO; Monconduit M; Harousseau JL; Duguet C; Facon T Thalidomide in patients with advanced myeloma: Survival prognostic factors. | 0 | 11 |
900 | 0 | 0 | 900 2000 BLOOD 96(11):167A-167A Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. | 0 | 3 |